Technical Analysis for BOLD - Boundless Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -7.50% | |
| Wide Bands | Range Expansion | -7.50% | |
| Gapped Up | Strength | -7.50% | |
| Fell Below 20 DMA | Bearish | -8.93% | |
| Wide Bands | Range Expansion | -8.93% | |
| Up 3 Days in a Row | Strength | -12.18% | |
| Stochastic Buy Signal | Bullish | -3.90% | |
| Multiple of Ten Bullish | Other | -0.56% | |
| New 52 Week Closing Low | Bearish | 5.89% | |
| Hot IPO Pullback | Bullish Swing Setup | 5.89% |
| Alert | Time |
|---|---|
| Down 5% | about 2 hours ago |
| Fell Below Previous Day's Low | about 2 hours ago |
| Fell Below 10 DMA | about 2 hours ago |
| 10 DMA Support | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 2 hours ago |
Get a Trading Assistant
- Earnings date: Unknown
Boundless Bio, Inc. Description
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Rare Diseases Molecular Biology Gene Therapy Muscular Dystrophy Applied Genetics Duchenne Muscular Dystrophy Myotonic Dystrophy Pompe Disease Gene Therapy Products Treatment Of Pompe Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.24 |
| 52 Week Low | 9.84 |
| Average Volume | 201,955 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 11.67 |
| 10-Day Moving Average | 11.01 |
| Average True Range | 1.02 |
| RSI (14) | 40.48 |
| ADX | 0.0 |
| +DI | 16.59 |
| -DI | 29.32 |
| Chandelier Exit (Long, 3 ATRs) | 12.19 |
| Chandelier Exit (Short, 3 ATRs) | 12.89 |
| Upper Bollinger Bands | 13.73 |
| Lower Bollinger Band | 9.61 |
| Percent B (%b) | 0.45 |
| BandWidth | 35.31 |
| MACD Line | -0.46 |
| MACD Signal Line | -0.47 |
| MACD Histogram | 0.0082 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.13 | ||||
| Resistance 3 (R3) | 13.11 | 12.54 | 12.85 | ||
| Resistance 2 (R2) | 12.54 | 12.12 | 12.55 | 12.75 | |
| Resistance 1 (R1) | 12.00 | 11.85 | 11.72 | 12.02 | 12.66 |
| Pivot Point | 11.43 | 11.43 | 11.29 | 11.44 | 11.43 |
| Support 1 (S1) | 10.89 | 11.01 | 10.61 | 10.91 | 10.26 |
| Support 2 (S2) | 10.32 | 10.74 | 10.33 | 10.17 | |
| Support 3 (S3) | 9.78 | 10.32 | 10.07 | ||
| Support 4 (S4) | 9.80 |
